This study audited pregnancies where the mother received tinzaparin (at any stage before delivery), with a primary objective of determining the maternal safety of this low molecular weight heparin when administered as treatment and/or prophylaxis; the secondary objective was to audit fetal and neonatal safety in this cohort. Efficacy outcomes were also recorded.
The audit period was 1996–2009; consecutive, retrospective pregnancy records at participating hospitals were reviewed. For those records documenting tinzaparin use and pregnancy outcome, information was extracted into a standardised case report form; these were reviewed for adverse events, which were submitted for adjudication by independent experts in obstetric medicine and haematology. Endpoints were presented using descriptive statistics for all pregnancies, and by reason for tinzaparin use (treatment of venous thromboembolism [VTE] and prophylaxis).
There were 28 participating hospital centres in eight countries (Belgium, Canada, Denmark, Ireland, Netherlands, Sweden, Spain and the UK). Data were collected from 1267 pregnancies (1120 women; 1303 fetuses); in 254 pregnancies the women received tinzaparin as treatment (median dose 13,000 international units [IU]/day, range 3500–23,100 IU/day; median duration 72 days; 94.1% once-daily), and in 1013 pregnancies the women received tinzaparin for prophylaxis (median dose 4500 IU/day, range 2500–21,811 IU/day, median duration 183 days, 94.6% once-daily). There were 871 (70.2%) vaginal deliveries (78 assisted) and 369 (29.8%) caesarean sections (27 delivery data missing). Overall, 495 (39.3%) women had neuraxial anaesthesia; however, there were no reported associated haematomas. There were no maternal deaths. Of pregnancies with available data (1060), 86.9% had blood loss ≤500 mL, 11.0% of >500 to ≤1000 mL, 0.9% >1000 to ≤1500 mL and 1.1% >1500 mL. There were 1245 (95.5%) live births, 15 (1.2%) stillbirths, 40 (3.1%) miscarriages and 3 (0.2%) terminations. Six (0.5%) neonatal deaths occurred (five at <27 weeks, one Ebstein's anomaly). No neonatal haemorrhages occurred. Adjudicated safety outcomes included 125 (9.9%) ‘any bleeding’ cases considered related to tinzaparin; 16 (1.3%) of these required medical intervention. In the treatment group, five (2%) recurrent VTEs were reported and 10 (1%) occurred in the prophylaxis group.
These data provide reassuring maternal and fetal outcome information in pregnancies exposed to tinzaparin.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study.Ann Intern Med. 2005; 143: 697-706
- Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn).Chest. 2008; 133: 844S-886S
- Pulmonary embolism in pregnancy.Lancet. 2010; 375: 500-512
- Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.Blood. 2005; 106: 401-407
- Venous thromboembolic disease and pregnancy.N Engl J Med. 2008; 359: 2025-2033
- Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.N Engl J Med. 1992; 326: 975-982
- A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.N Engl J Med. 1997; 337: 663-669
- Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.Am J Obstet Gynecol. 2004; 190: 495-501
Centre for Maternal and Child Enquiries (CMACE) Perinatal Mortality 2009: United Kingdom. CMACE: London, 2011. Accessed: 18 April 2011. Available at: http://www.cemach.org.uk/getattachment/87faf695-b2cb-43d0-8eb8-9c2260789ee4/Perinatal-Mortality-2009.aspx.
- The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey.Br J Haematol. 2007; 139: 545-558
- Antenatal pulmonary embolism: risk factors, management and outcomes.Br J Obstet Gynaecol. 2008; 115: 453-461
- Treatment of established thrombosis in pregnancy with tinzaparin, a study of 32 patients for one centre.Pathophysiol Haemost Thromb. 2006; 35: A50
- Osteopenic fractures in pregnancy: is low molecular weight heparin (LMWH) implicated?.J Obstet Gynecol. 2008; 28: 539-542
- Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes.Eur J Obstet Gynecol Reprod Biol. 2010; 149: 47-51
- Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.Thromb Haemost. 1997; 77: 39-43
- Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.Thromb Haemost. 2007; 98: 1237-1245
- Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity?.Lupus. 2010; 19: 3-12
- Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.Thromb Haemost. 2002; 87: 182-186
- Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial.J Thromb Haemost. 2007; 5: 1600-1606
Published online: September 19, 2011
Accepted: August 31, 2011
Received in revised form: July 14, 2011
Received: June 1, 2011
© 2011 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.